These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6843182)

  • 1. Pindolol--a new beta-adrenergic blocking agent with intrinsic sympathomimetic activity in the management of mild and moderate hypertension.
    Schirger A; Sheps SG; Spiekerman RE; Harman TR; Kleven MK
    Mayo Clin Proc; 1983 May; 58(5):315-8. PubMed ID: 6843182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrinsic sympathomimetic activity of pindolol. Evidence for interaction with pretreatment sympathetic tone.
    Plotnick GD; Fisher ML; Hamilton JH; Hamilton BP
    Am J Med; 1983 Apr; 74(4):625-9. PubMed ID: 6340489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Labetalol and pindolol in the treatment of hypertension: a comparative study.
    Romo M; Halttunen P; Saarinen P; Sarna S
    Ann Clin Res; 1979 Dec; 11(6):249-52. PubMed ID: 398184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The antihypertensive action of the beta adrenergic blocking agent Visken (pindolol, LB 46) in mild and moderate hypertension].
    Török E; Jávor T; Szám I; Gábor G
    Orv Hetil; 1976 Mar; 117(10):593-8. PubMed ID: 1250586
    [No Abstract]   [Full Text] [Related]  

  • 5. Twice-daily pindolol and alprenolol in essential hypertension of moderate severity.
    Hartikainen M; Heikkilä J
    Ann Clin Res; 1976 Apr; 8(2):85-92. PubMed ID: 779590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Potassium metabolism in combined administration of pindolol and clopamide in long-term treatment of hypertension (author's transl)].
    Faupel RP; Gotzen R
    Dtsch Med Wochenschr; 1978 Oct; 103(41):1602-5. PubMed ID: 100301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of hypertension with a new beta-adrenergic blocking agent, pindolol (Viskén)].
    Persson I; Ulrich J
    Ugeskr Laeger; 1973 May; 135(20):968-70. PubMed ID: 4755952
    [No Abstract]   [Full Text] [Related]  

  • 8. Beta blockers with intrinsic sympathomimetic activity.
    White WB
    Am Fam Physician; 1985 Jan; 31(1):115-8. PubMed ID: 2857059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group.
    J Hum Hypertens; 1992 Jun; 6(3):181-4. PubMed ID: 1352827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pressor reaction of hypertonic subjects to physical exercise of submaximal intensity under the influence of beta-adrenergic block (Pindolol) (author's transl)].
    Chrástek J; Boudová L; Kavánková M; Benes K; Krízek V; Matousek O
    Sb Lek; 1973 Oct; 75(10):301-11. PubMed ID: 4759769
    [No Abstract]   [Full Text] [Related]  

  • 11. Pindolol and systolic time intervals in patients with hypertension.
    Hammond JJ; Kirkendall WM; Jacks-Nagle VL; Plotnick GD; Fisher ML; Hamilton JH; Robinson M; Carliner NH; Janoski AH; Hamilton BP
    Am Heart J; 1982 Aug; 104(2 Pt 2):456-64. PubMed ID: 7102532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pindolol: a review of its pharmacology, pharmacokinetics, clinical uses, and adverse effects.
    Golightly LK
    Pharmacotherapy; 1982; 2(3):134-47. PubMed ID: 6133267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antihypertensive therapy with a new beta-blocking agent Timolol. Double blind study and comparison with Alprenolol and Pindolol (author's transl)].
    Wessels F; Heinze A; Werth HW
    Med Klin; 1977 Oct; 72(41):1689-95. PubMed ID: 335203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of a centrally acting antihypertensive agent and beta-adrenergic blocking agents for the treatment of hypertension.
    Morgan TO
    J Cardiovasc Pharmacol; 1984; 6 Suppl 5():S808-13. PubMed ID: 6084130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hypertension with the beta-receptor-antagonist pindolol (Viskèn). A comparison with chlorthalidone (Hygroton)].
    Schaffalitzky de Muckadel ; Gyntelberg F
    Ugeskr Laeger; 1973 May; 135(20):971-4. PubMed ID: 4585570
    [No Abstract]   [Full Text] [Related]  

  • 16. Pindolol in hypertension: twice-daily versus thrice-daily dosage.
    Waal-Manning HJ; Wood AJ
    Med J Aust; 1975 Aug; 2(7):274-5. PubMed ID: 1160793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of pindolol dosage in hypertension by automatic indirect BP monitoring.
    Sheps SG; Schirger A; Spiekerman RE; Harman TR; O'Brien PC; Kleven MK; Kremer-Simpson K
    Arch Intern Med; 1985 Jan; 145(1):54-7. PubMed ID: 3970647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pindolol: a comparison with other antihypertensive drugs and a double-blind placebo trial.
    Waal-Manning HJ; Simpson FO
    N Z Med J; 1974 Aug; 80(522):151-7. PubMed ID: 4608769
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of pindolol in the treatment of hypertension.
    Sedgwick JP; Crowder D
    Curr Med Res Opin; 1975; 3(2):89-94. PubMed ID: 1095311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-a-day pindolol in hypertension.
    Traub YM; Rosenfeld JB
    Clin Pharmacol Ther; 1977 May; 21(5):588-92. PubMed ID: 322923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.